<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563340</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-KTx-cAMR-150926</org_study_id>
    <nct_id>NCT02563340</nct_id>
  </id_info>
  <brief_title>Effect of BM-MSCs on Chronic AMR After Kidney Transplantation</brief_title>
  <official_title>Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Chronic Antibody-mediated Rejection (cAMR) After Kidney Transplantation: A Multi-center Perspective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <brief_summary>
    <textblock>
      This study is designed to investigate the efficacy and safety of allogeneic bone&#xD;
      marrow-derived mesenchymal stem cells (BM-MSCs) on chronic antibody-mediated rejection (cAMR)&#xD;
      after kidney transplantation. Chronic AMR is diagnosed according to Banff criteria 2013 based&#xD;
      on renal graft biopsy and donor specific antibodies (DSA) examination. cAMR patients are&#xD;
      assigned to MSCs group or control group. Patients in control group are prescribed to current&#xD;
      desensitization therapy including at least one of the following treatments: plasmapheresis&#xD;
      (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib, depending on individual&#xD;
      pathological and immunological features (eg. DSA type and titer) of each study subjects.&#xD;
      Patients in MSCs group receive additional BM-MSCs therapy besides desensitization treatments&#xD;
      as in control group. Allogeneic BM-MSCs (1*10^6/kg) are intravenously administered every two&#xD;
      weeks for four consecutive doses. All cAMR patients are followed up for one year. Renal&#xD;
      function, DSA level, pathological features, patient/graft survival, and severe adverse events&#xD;
      are monitored during the follow-up period. Immunological features of patients in both groups&#xD;
      are consecutively examined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>12 months</time_frame>
    <description>eGFR at month 12 after enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient survival rate</measure>
    <time_frame>12 months</time_frame>
    <description>patient survival rate at month 12 after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival rate</measure>
    <time_frame>12 months</time_frame>
    <description>graft survival rate at month 12 after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor specific antibody (DSA) level</measure>
    <time_frame>12 months</time_frame>
    <description>Change of DSA level up to 12 months after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological manifestation</measure>
    <time_frame>12 months</time_frame>
    <description>Change of pathological scores according to Banff 2013 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>MSCs group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BM-MSCs</intervention_name>
    <description>BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.</description>
    <arm_group_label>MSCs group</arm_group_label>
    <other_name>allogeneic bone marrow-derived MSCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Desensitization therapy (PP, IVIG, rituximab or Bortezomib)</intervention_name>
    <description>At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>MSCs group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  kidney transplantation&#xD;
&#xD;
          -  cAMR diagnosis is determined based on renal graft biopsy and DSA examination&#xD;
&#xD;
          -  Patient is willing and capable of giving written informed consent for study&#xD;
             participation and able to participate in the study for 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined or multi-organ transplantation&#xD;
&#xD;
          -  Women who are pregnant, intend to become pregnant in the next 1 years, breastfeeding,&#xD;
             or have a positive pregnancy test on enrollment or prior to study medication&#xD;
             administration&#xD;
&#xD;
          -  Donors or recipients are known hepatitis C antibody-positive or polymerase chain&#xD;
             reaction (PCR) positive for hepatitis C&#xD;
&#xD;
          -  Donors or recipients are known hepatitis B surface antigen-positive or PCR positive&#xD;
             for hepatitis B&#xD;
&#xD;
          -  Donors or recipients are known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Patients with active infection&#xD;
&#xD;
          -  Recipients with a history of substance abuse (drugs or alcohol) within the past 6&#xD;
             months, or psychotic disorders that are not capable with adequate study follow- up&#xD;
&#xD;
          -  Patients with severe cardiovascular dysfunction&#xD;
&#xD;
          -  WBC&lt;3*10^9/L or RBC &lt;5g/dL&#xD;
&#xD;
          -  Highly allergic constitution or having severe history of allergies&#xD;
&#xD;
          -  Patients with active peptic ulcer disease, chronic diarrhea, or gastrointestinal&#xD;
             problem affect absorption&#xD;
&#xD;
          -  Patients with a history of cancer within the last 5 years&#xD;
&#xD;
          -  Prisoner or patients compulsorily detained (involuntarily incarcerated) for treatment&#xD;
             or either a psychiatric or physical (e.g. infectious disease) illness&#xD;
&#xD;
          -  Renal graft function deteriorates due to non-immunological complication, such as&#xD;
             surgical issues or drug nephrotoxicity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changxi Wang, M.D., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changxi Wang, M.D., Ph.D</last_name>
    <phone>86-20-87333428</phone>
    <email>wangchx@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Longshan Liu, M.D., Ph.D</last_name>
    <phone>86-20-87306082</phone>
    <email>liulshan@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23263506</url>
    <description>Previous publication</description>
  </link>
  <reference>
    <citation>Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W, Li X, Chen Z, Ma J, Liao D, Li G, Fang J, Pan G, Xiang AP. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2013 Jan 15;95(1):161-8. doi: 10.1097/TP.0b013e3182754c53. Erratum in: Transplantation. 2014 Mar 27;97(6):e37. Pan, Guanghui [added].</citation>
    <PMID>23263506</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Changxi Wang</investigator_full_name>
    <investigator_title>Director of Organ Transplant Center</investigator_title>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>antibody-mediated rejection</keyword>
  <keyword>mesenchymal stem cell therapy</keyword>
  <keyword>donor specific antibody</keyword>
  <keyword>acute rejection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

